UCB-1184197

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597779

CAS#: 455264-30-9

Description: UCB-1184197 is an alpha4 integrin inhibitor.


Chemical Structure

img
UCB-1184197
CAS# 455264-30-9

Theoretical Analysis

MedKoo Cat#: 597779
Name: UCB-1184197
CAS#: 455264-30-9
Chemical Formula: C28H29BrN4O3
Exact Mass: 548.14
Molecular Weight: 549.460
Elemental Analysis: C, 61.21; H, 5.32; Br, 14.54; N, 10.20; O, 8.74

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: UCB-1184197; UCB 1184197; UCB1184197; CDP323; CDP 323; CDP-323;

IUPAC/Chemical Name: ethyl (S)-3-(4-((2,7-naphthyridin-1-yl)amino)phenyl)-2-((2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino)propanoate

InChi Key: QCYAXXZCQKMTMO-QFIPXVFZSA-N

InChi Code: InChI=1S/C28H29BrN4O3/c1-2-36-27(35)22(33-24-23(29)25(34)28(24)12-4-3-5-13-28)16-18-6-8-20(9-7-18)32-26-21-17-30-14-10-19(21)11-15-31-26/h6-11,14-15,17,22,33H,2-5,12-13,16H2,1H3,(H,31,32)/t22-/m0/s1

SMILES Code: O=C(OCC)[C@H](CC1=CC=C(NC2=NC=CC3=C2C=NC=C3)C=C1)NC4=C(Br)C(C45CCCCC5)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 549.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lahiffe BJ, Caffesse RG, Nasjleti CE. Healing of periodontal flaps following use of MBR 4197 (flucrylate) in rhesus monkeys. A clinical and histological evaluation. J Periodontol. 1978 Dec;49(12):635-45. PubMed PMID: 83358.

2: Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H; TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jun;15(7):689-99. doi: 10.1016/S1470-2045(14)70178-0. Epub 2014 May 2. PubMed PMID: 24793816.

3: Morone G, Tramontano M, Iosa M, Shofany J, Iemma A, Musicco M, Paolucci S, Caltagirone C. The efficacy of balance training with video game-based therapy in subacute stroke patients: a randomized controlled trial. Biomed Res Int. 2014;2014:580861. doi: 10.1155/2014/580861. Epub 2014 May 5. PubMed PMID: 24877116; PubMed Central PMCID: PMC4026958.

4: Huang ZQ. [The present status of surgical treatment of intrahepatic lithiasis in a nation-wide survey in China of 4197 operative cases 1981-1985]. Zhonghua Wai Ke Za Zhi. 1988 Sep;26(9):513-22, 572. Chinese. PubMed PMID: 3072167.

5: McGraw VA, Caffesse RG, Nasjleti CE. Healing of periodontal flaps following use of MBR 4197 (flucrylate) in rhesus monkeys. A biometric and histometric evaluation. J Periodontol. 1979 Jun;50(6):305-10. PubMed PMID: 110916.

6: Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016 Nov 7;16(1):648. PubMed PMID: 27821093; PubMed Central PMCID: PMC5100179.

7: Müller WU, Bauch T, Streffer C, Niedereichholz F, Böcker W. Comet assay studies of radiation-induced DNA damage and repair in various tumour cell lines. Int J Radiat Biol. 1994 Mar;65(3):315-9. PubMed PMID: 7908310.

8: Leek R, Aldag E, Nadeem I, Gunabushanam V, Sahajpal A, Kramer DJ, Walsh TJ. Scedosporiosis in a Combined Kidney and Liver Transplant Recipient: A Case Report of Possible Transmission from a Near-Drowning Donor. Case Rep Transplant. 2016;2016:1879529. doi: 10.1155/2016/1879529. Epub 2016 Dec 13. PubMed PMID: 28070441; PubMed Central PMCID: PMC5187490.

9: Boulet SL, Mehta A, Kissin DM, Warner L, Kawwass JF, Jamieson DJ. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. JAMA. 2015 Jan 20;313(3):255-63. doi: 10.1001/jama.2014.17985. PubMed PMID: 25602996; PubMed Central PMCID: PMC4343214.

10: Morone G, Masiero S, Werner C, Paolucci S. Advances in neuromotor stroke rehabilitation. Biomed Res Int. 2014;2014:236043. doi: 10.1155/2014/236043. Epub 2014 Jun 19. PubMed PMID: 25050330; PubMed Central PMCID: PMC4090496.

11: Martin TR, Onstad GR, Silvis SE. Endoscopic control of massive upper gastrointestinal bleeding with a tissue adhesive (MBR 4197). Gastrointest Endosc. 1977 Nov;24(2):74-6. PubMed PMID: 304024.

12: Arts RJ, Plantinga TS, Tuit S, Ulas T, Heinhuis B, Tesselaar M, Sloot Y, Adema GJ, Joosten LA, Smit JW, Netea MG, Schultze JL, Netea-Maier RT. Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages. Oncoimmunology. 2016 Sep 9;5(12):e1229725. doi: 10.1080/2162402X.2016.1229725. eCollection 2016. PubMed PMID: 28123869; PubMed Central PMCID: PMC5213309.

13: Peura DA, Johnson LF, Burkhalter EL, Hogan WJ, LoGuidice JA, Schapiro M, Klasky I, Belsito AA, Butler ML, Silvis SE. Use of trifluoroisopropyl cyanoacrylate polymer (MBR 4197) in patients with bleeding peptic ulcers of the stomach and duodenum: a randomized controlled study. J Clin Gastroenterol. 1982 Aug;4(4):325-8. PubMed PMID: 6749960.

14: Sangiorgi B, Panepucci RA. Modulation of Immunoregulatory Properties of Mesenchymal Stromal Cells by Toll-Like Receptors: Potential Applications on GVHD. Stem Cells Int. 2016;2016:9434250. Epub 2016 Sep 21. Review. PubMed PMID: 27738438; PubMed Central PMCID: PMC5050362.

15: Babick F, Mielke J, Wohlleben W, Weigel S, Hodoroaba VD. How reliably can a material be classified as a nanomaterial? Available particle-sizing techniques at work. J Nanopart Res. 2016;18:158. Epub 2016 Jun 14. PubMed PMID: 27375365; PubMed Central PMCID: PMC4908171.

16: Blotsky A, Mardini L, Jayaraman D. Impact of a Local Low-Cost Ward-Based Response System in a Canadian Tertiary Care Hospital. Crit Care Res Pract. 2016;2016:1518760. Epub 2016 Oct 17. PubMed PMID: 27830088; PubMed Central PMCID: PMC5086497.

17: Hatemi AC, Çeviker K, Tongut A, Özgöl İ, Mert M, Kaya A. Oxidant Status following Cardiac Surgery with Phosphorylcholine-Coated Extracorporeal Circulation Systems. Oxid Med Cell Longev. 2016;2016:3932092. Epub 2016 Nov 23. PubMed PMID: 27994711; PubMed Central PMCID: PMC5141305.

18: Caiata-Zufferey M, Pagani O, Cina V, Membrez V, Taborelli M, Unger S, Murphy A, Monnerat C, Chappuis PO. Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genet Med. 2015 Sep;17(9):726-32. doi: 10.1038/gim.2014.183. Epub 2014 Dec 11. PubMed PMID: 25503500.

19: Niu B, Scott AD, Sengupta S, Bailey MH, Batra P, Ning J, Wyczalkowski MA, Liang WW, Zhang Q, McLellan MD, Sun SQ, Tripathi P, Lou C, Ye K, Mashl RJ, Wallis J, Wendl MC, Chen F, Ding L. Protein-structure-guided discovery of functional mutations across 19 cancer types. Nat Genet. 2016 Aug;48(8):827-37. doi: 10.1038/ng.3586. Epub 2016 Jun 13. Erratum in: Nat Genet. 2017 Jul 27;49(8):1286. PubMed PMID: 27294619; PubMed Central PMCID: PMC5315576.

20: Mose S, Karapetian M, Jüling-Pohlit L, Taborski B, Damrau M, Ramm U, Rahn A, Böttcher HD. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Res. 2000 Jan-Feb;20(1A):401-5. PubMed PMID: 10769687.